State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
J Mater Chem B. 2021 Jan 28;9(3):612-633. doi: 10.1039/d0tb02139c.
rHDL is a synthesized drug delivery nanoplatform exhibiting excellent biocompatibility, which possesses most of the advantages of HDL. rHDL shows almost no toxicity and can be degraded to non-toxic substances in vivo. The severe limitation of the application of various antitumor agents is mainly due to their low bioavailability, high toxicity, poor stability, etc. Favorably, antitumor drug-loaded rHDL nanoparticles (NPs), which are known as an important drug delivery system (DDS), help to change the situation a lot. This DDS shows an outstanding active-targeting ability towards tumor cells and improves the therapeutic effect during antitumor treatment while overcoming the shortcomings mentioned above. In the following text, we will mainly focus on the various applications of rHDL in tumor targeted therapy by describing the properties, preparation, receptor active-targeting ability and antitumor effects of antineoplastic drug-loaded rHDL NPs.
rHDL 是一种合成的药物递送纳米平台，具有出色的生物相容性，拥有 HDL 的大部分优点。rHDL 几乎没有毒性，并且可以在体内降解为无毒物质。各种抗肿瘤药物应用的严重限制主要是由于其生物利用度低、毒性高、稳定性差等。有利的是，载有抗肿瘤药物的 rHDL 纳米颗粒（NPs），作为一种重要的药物递送系统（DDS），有助于改变这种情况。该 DDS 对肿瘤细胞表现出出色的主动靶向能力，并在抗肿瘤治疗中提高了治疗效果，同时克服了上述缺点。在下面的文本中，我们将主要通过描述载有抗肿瘤药物的 rHDL NPs 的特性、制备、受体主动靶向能力和抗肿瘤作用，来重点介绍 rHDL 在肿瘤靶向治疗中的各种应用。
